RU2015112297A - Способы идентификации вич-нейтрализующих антител - Google Patents

Способы идентификации вич-нейтрализующих антител Download PDF

Info

Publication number
RU2015112297A
RU2015112297A RU2015112297A RU2015112297A RU2015112297A RU 2015112297 A RU2015112297 A RU 2015112297A RU 2015112297 A RU2015112297 A RU 2015112297A RU 2015112297 A RU2015112297 A RU 2015112297A RU 2015112297 A RU2015112297 A RU 2015112297A
Authority
RU
Russia
Prior art keywords
binding
paragraphs
fusion protein
hiv
sample
Prior art date
Application number
RU2015112297A
Other languages
English (en)
Russian (ru)
Inventor
АРБУЭС Хулиан Мигель БЛАНКО
МОЛИНА Хорхе КАРРИЛЬО
Original Assignee
Лабораторьос Дель Др. Эстеве, С.А.
Фундасио Привада Институт Де Ресерка Де Ля Сида - Кайкса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораторьос Дель Др. Эстеве, С.А., Фундасио Привада Институт Де Ресерка Де Ля Сида - Кайкса filed Critical Лабораторьос Дель Др. Эстеве, С.А.
Publication of RU2015112297A publication Critical patent/RU2015112297A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
RU2015112297A 2012-09-06 2013-09-06 Способы идентификации вич-нейтрализующих антител RU2015112297A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382342.9 2012-09-06
EP12382342.9A EP2706356A1 (en) 2012-09-06 2012-09-06 Methods for identifying HIV neutralizing antibodies
PCT/EP2013/068446 WO2014037490A1 (en) 2012-09-06 2013-09-06 Methods for identifying hiv neutralizing antibodies

Publications (1)

Publication Number Publication Date
RU2015112297A true RU2015112297A (ru) 2016-10-27

Family

ID=46829683

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015112297A RU2015112297A (ru) 2012-09-06 2013-09-06 Способы идентификации вич-нейтрализующих антител

Country Status (16)

Country Link
US (1) US9952218B2 (https=)
EP (2) EP2706356A1 (https=)
JP (1) JP6282655B2 (https=)
KR (1) KR20150081255A (https=)
CN (1) CN104755933B (https=)
AU (1) AU2013311626A1 (https=)
BR (1) BR112015004970A2 (https=)
CA (1) CA2884165A1 (https=)
ES (1) ES2643268T3 (https=)
IL (1) IL237613A0 (https=)
IN (1) IN2015DN02730A (https=)
MX (1) MX2015003047A (https=)
PT (1) PT2893349T (https=)
RU (1) RU2015112297A (https=)
WO (1) WO2014037490A1 (https=)
ZA (1) ZA201502210B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106166313B (zh) * 2016-07-01 2018-09-07 浙江大学 一种艾滋病孕妇血液净化器
CN106075626B (zh) * 2016-07-01 2018-06-26 浙江大学 一种艾滋病血液净化治疗仪

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US7115262B1 (en) * 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
WO2003040311A2 (en) * 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
EP1523492A4 (en) * 2002-07-23 2006-05-10 Univ Duke IGG FC / HIV GP120 / C3D FUSION PROTEIN
US8197819B2 (en) * 2004-06-08 2012-06-12 Novartis Vaccines And Diagnostics, Inc. Env polypeptide complexes and methods of use
ATE471947T1 (de) * 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
CN101551392A (zh) * 2008-01-22 2009-10-07 厦门大学 一种检测人乳头瘤病毒中和抗体的方法
CN101846679A (zh) * 2009-03-25 2010-09-29 邢安辉 筛选含有外源融合基因HIV/env/IFNα-2b的重组痘苗病毒的方法
EP3957651A1 (en) * 2010-05-21 2022-02-23 The United States of America, as Represented By the Secretary, Department of Health and Human Services High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins

Also Published As

Publication number Publication date
PT2893349T (pt) 2018-04-12
WO2014037490A1 (en) 2014-03-13
IN2015DN02730A (https=) 2015-09-04
MX2015003047A (es) 2015-07-14
AU2013311626A1 (en) 2015-04-30
KR20150081255A (ko) 2015-07-13
CN104755933B (zh) 2017-06-09
CA2884165A1 (en) 2014-03-13
EP2706356A1 (en) 2014-03-12
EP2893349B1 (en) 2017-08-16
CN104755933A (zh) 2015-07-01
EP2893349A1 (en) 2015-07-15
JP6282655B2 (ja) 2018-02-21
ZA201502210B (en) 2016-11-30
JP2015530575A (ja) 2015-10-15
US9952218B2 (en) 2018-04-24
ES2643268T3 (es) 2017-11-21
US20150233924A1 (en) 2015-08-20
IL237613A0 (en) 2015-04-30
HK1211694A1 (en) 2016-05-27
BR112015004970A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
Karsten et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis
Pötzsch et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies
Scheid et al. A method for identification of HIV gp140 binding memory B cells in human blood
Sangesland et al. Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus
Gray et al. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region
Chen et al. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein
Longo et al. Multiple antibody lineages in one donor target the glycan-V3 supersite of the HIV-1 envelope glycoprotein and display a preference for quaternary binding
Moreno et al. MAb‐based competitive ELISA for the detection of antibodies against influenza D virus
Thornlow et al. Altering the immunogenicity of hemagglutinin immunogens by hyperglycosylation and disulfide stabilization
JP2010526880A5 (https=)
RU2013129203A (ru) Моноклональное антитело, распознающее белок l2 папилломавируса человека (впч), и способ определения титра впч-нейтрализующего антитела, использующий такое антитело
Chernyshev et al. Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
Cheng et al. Immune monitoring reveals fusion peptide priming to imprint cross-clade HIV-neutralizing responses with a characteristic early B cell signature
Jia et al. Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity
Meng et al. Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells
Yang et al. Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V (D) J sequencing
Paciello et al. Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses
Paparoditis et al. Site‐specific serology unveils cross‐reactive monoclonal antibodies targeting influenza A hemagglutinin epitopes
Ataca et al. Modulating the immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stem
Yisimayi et al. Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine
RU2015112297A (ru) Способы идентификации вич-нейтрализующих антител
Kostin et al. An ELISA platform for the quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies as an alternative to monitoring of the virus-neutralizing activity
Liu et al. SARS-CoV-2–reactive mucosal B cells in the upper respiratory tract of uninfected individuals
Yang et al. Identification of non-HIV immunogens that bind to germline b12 predecessors and prime for elicitation of cross-clade neutralizing HIV-1 antibodies
Ehling et al. Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20160907